FMT in Children With Autism and Gastrointestinal Symptoms

NCT ID: NCT04246398

Last Updated: 2020-02-05

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-02-29
• Study Completion Date: 2022-12-31

Brief Summary

1. ASD children with gastrointestinal problems that interfere with daily routine will be recruited at the center for Autism led by Prof Zachor, and at the Pediatric Neurology & Development Center at Shamir Medical Center. Publications in the social media- facebook and support groups for Autism will also be used. The decision whether or not to initiate any medical treatment will not be influenced by the study investigators and will be made solely by the treating doctor.

2. If possible, participants will provide informed consent after receiving a thorough explanation by the study team, as will both parents or other legal guardians.

3. Two groups randomization will be performed, group A and group B. The group randomization will be double blinded.

4. Participants randomized to group A will receive 10 capsules FMT twice a week for 3 weeks, and at week 12 followed by 3 weeks placebo twice a week.

5. Participants randomized to group B will receive 10 capsules placebo twice a week for 3 weeks and at week 12 followed by 3 weeks FMT twice a week.

6. At baseline, participants will undergo a full physical examination, vital signs, medical questionnaire, ROME III questionnaire for kids >age4 />age 10, ATN-GISSI-17 questionnaire, Aut-Eat questionnaire regarding eating habbits, the Social Responsiveness Scale (SRS) and the Adaptive Behavior Assessment System (ABAS).

7. Parents/ care providers will fill a daily symptoms follow-up questionnaire at baseline

8. Fecal samples will be provided for analysis of microbiome and proteome at beseline, weeks 3,12, 15 and 6+9 months.

9. At each FMT/Placebo administration a short questionnaire asking about possible adverse events, GI symptoms, overall well-being, and medication changes will be administered

Detailed Description

About 50% of children with Autism spectrum disorder (ASD) tend to suffer from one or more gastrointestinal (GI) symptoms.The GI symptoms vary from constipation (~20%), diarrhea (~14%), Abdominal pain/discomfort (14%), bloating (12%), incontinence (12%), reflux (7.4%), nausia (6%) and difficult with bowel movements (6%).

The severity of ASD is associated with the observed GI symptoms, although no cause-effect relationship between GI symptoms and ASD was proven so far. ASD with GI symptoms patients might display significant behavioral manifestations, such as anxiety, self-injury and aggression and these may be attributed to the GI symptoms themselves. Therefore alleviation of the GI symptoms could be important also for improvement of ASD.

In addition to the possibility that the nervous system influences the gut and the GI symptoms, there is also the possibility that the gut and the microbiome within the gut may influence the central nervous system.

Considering the findings that children with ASD have a history of using significantly more antibiotics and that gut permeability increases in ASD it is reasonable to assume that ASD patients have distinct microbiomes and gut metabolites.

Nevertheless, perhaps changing the gut microbiome could lead to improvement in some of the symptoms. So far, studies on influencing ASD (behavior and GI symptoms) by addressing the gut microbiome are optimistic but mostly open-labeled and still inconclusive.

Conditions

Children With Autism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Fecal microbiota transplant (FMT)

10 capsules per dose for 6 consecutive weeks, twice a week, for a total of 120 capsules.

Each inoculum will be prepared from the feces of 1 donor and a dose of 10 capsules contains sieved, concentrated material derived from a mean of 10 grams of fecal matter. Donors are healthy, nonpregnant adults aged 18 to 50 years, taking no medications, and with a normal body mass index (18.5-25 [calculated as weight in kilograms divided by height in meters squared]).

Group Type: EXPERIMENTAL

FMT

Intervention Type: OTHER

Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.

Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration.

placebo

Placebo capsules will consist of a combination of saline/glycerol (same vehicle as FMT capsules). The inner capsules is dark (green colored), so the general appearance of the capsules is the same to the people who do not prepare them.

Group Type: PLACEBO_COMPARATOR

FMT - placebo

Intervention Type: OTHER

Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.

Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration.

Interventions

FMT

Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.

Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration.

Intervention Type: OTHER

FMT - placebo

Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.

Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration.

Intervention Type: OTHER

Other Intervention Names

Fecal microbiota transplant

Eligibility Criteria

Inclusion Criteria

• ASD Boys or girls 7 - 20 years of age
• suffering gastro-intestinal symptoms and/or food selectivity that interfere with daily routine
• Patients not started on immune-suppressive or anti-inflammatory medications.
• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Women of childbearing potential will have a urine pregnancy test, which must be negative, on Study Day 1, prior to receiving FMT. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for 3 months after FMT.
• Hasn't taken antibiotics 2 days prior to 1st visit.
• Ability of parents or other legal guardian to understand and the willingness to sign a written informed consent document, including the willingness to accept risk of unrelated donor stool.
• Ability to swallow oral medications.

Exclusion Criteria

• Severe GI problems that require immediate treatment (life-threatening).

• recent/scheduled surgeries
• diagnosed as severely malnourished or underweight
• diagnosed with a single-gene disorder
• major brain malformations
• inflammatory bowel diseases
• known positive serology for celiac disease or eosinophilic esophagitis
• Pregnancy / breast-feeding
• Using immune-suppressive or anti-inflammatory medications
• Active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
• Delayed gastric emptying syndrome
• Known chronic aspiration
• History of significant allergy to foods
• Unable to swallow pills

• Minimum Eligible Age: 7 Years
• Maximum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assaf Harofeh MC

OTHER_GOV

Sponsor Role: lead

Responsible Party

Assaf Harofeh MC

Dr.Ilan Youngster, Head, The Center for Translational Microbiome Research at Shamir Medical Center

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Assaf-HarofehMC

Ẕerifin, , Israel

Countries

Israel

Central Contacts

Ilan Youngster, M.D

Role: CONTACT

youngsteri@shamir.gov.il

0506301191

Other Identifiers

0052-19-ASF

Identifier Type: -

Identifier Source: org_study_id